# BAX Stock vs the S&P 500: Returns, Risk and Crash History

> Baxter International Inc., healthcare (market value $13.5 billion), an S&P 500 member: how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Source: https://www.exent.ai/stocks/bax · Reviewed by David, Senior Analyst, Exent · Published Nov 16, 2026 · Updated Nov 16, 2026

## Key takeaways

- BAX returned −67.9% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it lagged the index.
- Its 5-year Sharpe ratio was −0.59 against 0.58 for the S&P 500.
- Its deepest crisis drawdown was −39.8% in the 2022 inflation bear market (S&P 500: −25.4%).
- Five‑year volatility was 36.1% and beta 0.68.
- 15 analysts rated it in the past year; 7% of their latest calls were Buy.
- BAX beat earnings estimates in 10 of its last 12 reports; the stock moved 7.7% on average, up or down, around each report.

## Did BAX beat the S&P 500?

Over the 5 years to Oct 30, 2026, Baxter International Inc. (BAX) returned **−67.9%** including dividends, versus **+75.9%** for the S&P 500 (SPY). It lagged the index by 143.8 percentage points, or −20.3% a year against +12.0%.

| Period | BAX | S&P 500 | BAX per year | S&P 500 per year | Result |
| --- | --- | --- | --- | --- | --- |
| 1 year | +24.8% | +12.0% | +24.8% | +12.0% | Beat |
| 3 years | −25.0% | +87.4% | −9.2% | +23.3% | Lagged |
| 5 years | −67.9% | +75.9% | −20.3% | +12.0% | Lagged |
| 10 years | −43.5% | +316.3% | −5.5% | +15.3% | Lagged |

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also [how to beat the S&P 500](https://www.exent.ai/beat-the-market).

BAX is in the [S&P 500](https://www.exent.ai/stocks/sp-500) (members as of Oct 20, 2026); the list shows every member’s return against the index.

## What Wall Street analysts say about BAX

In the 12 months to 30 days ago, 15 analysts published 107 ratings on BAX. Their latest calls were 7% Buy, 79% Hold and 14% Sell. 3 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $23.83 (range $20.00–$28.00), −8.9% from the last price. Remember that the average analyst’s target is hit only about half the time: [how accurate are price targets?](https://www.exent.ai/resources/are-analyst-price-targets-accurate)

| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
| --- | --- | --- | --- |
| [Pito Chickering](https://www.exent.ai/analysts/pito-chickering) | [Deutsche Bank ](https://www.exent.ai/firms/deutsche-bank) | 4.6★ | 62.4% |
| [Matthew Taylor](https://www.exent.ai/analysts/matthew-taylor) | [Jefferies](https://www.exent.ai/firms/jefferies) | 4.6★ | 35.4% |
| [Vijay Kumar](https://www.exent.ai/analysts/vijay-kumar) | [Evercore ISI](https://www.exent.ai/firms/evercore-isi) | 4.5★ | 55.6% |

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on BAX are, their live calls and the median target of only the top‑rated analysts are in [Exent Gems](https://www.exent.ai/radar).

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. [Unlock the top 50 analysts](https://www.exent.ai/radar).

## BAX returns by year vs the S&P 500

BAX beat the S&P 500 in 2 of the 9 full calendar years shown.

| Year | BAX | S&P 500 | Difference |
| --- | --- | --- | --- |
| 2026 (to Oct 30, 2026) | +20.5% | +11.7% | +8.8% |
| 2025 | −33.3% | +17.7% | −51.0% |
| 2024 | −22.4% | +24.9% | −47.3% |
| 2023 | −21.9% | +26.2% | −48.1% |
| 2022 | −39.6% | −18.2% | −21.4% |
| 2021 | +8.5% | +28.7% | −20.2% |
| 2020 | −3.0% | +18.3% | −21.3% |
| 2019 | +28.4% | +31.2% | −2.8% |
| 2018 | +2.9% | −4.6% | +7.5% |
| 2017 | +47.7% | +21.7% | +26.0% |

## BAX risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, BAX had a Sharpe ratio of **−0.59** against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 34.3% and its beta 0.68: it tended to move about 0.7× as much as the market.

| Metric | BAX | S&P 500 |
| --- | --- | --- |
| Annual return | −20.3% | +12.0% |
| Volatility (annualized) | 34.3% | 15.5% |
| Sharpe ratio | −0.59 | 0.58 |
| Sortino ratio | −0.74 | 0.91 |
| Max drawdown (month-end) | −78.5% | −23.9% |
| Beta to the S&P 500 | 0.68 | 1.00 |

[Sharpe](https://www.exent.ai/learn/sharpe-ratio) divides return above cash by total volatility; [Sortino](https://www.exent.ai/learn/sortino-ratio) counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

## How BAX behaved in past crashes

BAX’s deepest fall in the crises below was **−39.8%** in the 2022 inflation bear market, against −25.4% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

| Crisis | BAX | S&P 500 | Loss on $100,000 |
| --- | --- | --- | --- |
| Global financial crisis (2007–09) | −31.8% | −56.5% | −$31,820 |
| 2018 trade-war selloff | −21.0% | −20.2% | −$21,020 |
| COVID crash (Feb–Mar 2020) | −23.2% | −34.1% | −$23,180 |
| 2022 inflation bear market | −39.8% | −25.4% | −$39,790 |
| 2025 tariff selloff | −23.5% | −19.0% | −$23,520 |

| Window | BAX max drawdown |
| --- | --- |
| Last 1 year | −29.1% |
| Last 3 years | −62.5% |
| Last 5 years | −80.6% |
| Last 10 years | −81.5% |

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the [crash test](https://www.exent.ai/tools/crash-test).

## What moves with BAX, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, BAX’s correlation with the S&P 500 was **0.31**, with the Nasdaq‑100 0.09, with long Treasuries (TLT) 0.27 and with gold (GLD) 0.15.

Adding a 5% BAX position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.3%.

| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
| --- | --- | --- | --- |
| [PLTR](https://www.exent.ai/stocks/pltr) | −0.18 | [ABT](https://www.exent.ai/stocks/abt) | 0.66 |
| [VRT](https://www.exent.ai/stocks/vrt) | −0.16 | [PM](https://www.exent.ai/stocks/pm) | 0.59 |
| [CDNS](https://www.exent.ai/stocks/cdns) | −0.16 | [CVS](https://www.exent.ai/stocks/cvs) | 0.54 |
| [TSLA](https://www.exent.ai/stocks/tsla) | −0.16 | [KO](https://www.exent.ai/stocks/ko) | 0.53 |
| [SNPS](https://www.exent.ai/stocks/snps) | −0.13 | [MRSH](https://www.exent.ai/stocks/mrsh) | 0.52 |

Holdings that are highly correlated behave like one position in a selloff. See [how to find hidden overlap](https://www.exent.ai/resources/is-my-portfolio-diversified).

## Latest BAX upgrades, downgrades and price‑target changes

| Date | Rating and target | Analyst |
| --- | --- | --- |
| Oct 29 | Target raised Hold Target $25, was $19 | [Matthew Taylor](https://www.exent.ai/analysts/matthew-taylor) Jefferies |
| Oct 7 | Target cut Sell Target $20, was $27 | Matt Miksic Barclays |
| Oct 7 | New coverage Sell Target $20, was $27 | Christopher Pasquale Barclays |
| Oct 5 | Target cut Hold Target $27, was $28 | Joanne Wuensch Citi |

Named analysts’ rating and price‑target changes on BAX in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in [Exent Gems](https://www.exent.ai/radar). [See all of the latest analyst upgrades and downgrades](https://www.exent.ai/analysts/upgrades).

## Do analysts get BAX right?

Of the 279 analyst price targets on BAX set from 2019 until a year ago, **30.5%** were reached within 12 months (data to Oct 20, 2026), 38.1 points below the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 47 days. The median target sat 12.7% above the share price on the day it was set.

Where analysts said BAX would be by now: a year ago, 8 analysts had a price target on BAX, and the median of their latest targets was **$21.50**. On Oct 20, 2026 BAX closed at $24.50, 14.0% above it.

- **30.5%** of targets reached within 12 months

- **47 days** median time to reach a target

- **+14.0%** price now vs the median target set a year ago

| After | Calls | Move on the call | 3 months vs S&P 500 |
| --- | --- | --- | --- |
| Upgrades of BAX | 8 | +0.6% | −5.7% |
| Upgrades, all stocks | 11,514 | +2.5% | +3.4% |
| Downgrades of BAX | 15 | −3.3% | −13.4% |
| Downgrades, all stocks | 10,700 | −3.0% | −1.6% |

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on BAX through Sep 15, 2026; analysts are not named here. [Do analyst upgrades move stocks?](https://www.exent.ai/resources/do-analyst-upgrades-move-stocks)

## How BAX moves after earnings

BAX beat the consensus earnings‑per‑share estimate in **10 of its last 12** quarterly reports, through the one on Jul 30, 2026, and the revenue estimate in 10 of 12. From the close before each report to the close after it, the stock moved 7.7% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 6 of the 12 reports. In 4 of the 10 beats the stock still fell.

- **10/12** earnings beats

- **±7.7%** average move per report

- **6/12** reports followed by a rise

| Report | EPS vs estimate | Revenue vs estimate | Stock move |
| --- | --- | --- | --- |
| Jul 30, 2026 | $0.56 vs $0.37 | +5.9% | +5.6% |
| Apr 30, 2026 | $0.36 vs $0.31 | +3.3% | +1.8% |
| Feb 12, 2026 | $0.44 vs $0.53 | +5.3% | −11.2% |
| Oct 30, 2025 | $0.69 vs $0.60 | +0.4% | −17.6% |
| Jul 31, 2025 | $0.59 vs $0.60 | −2.3% | −21.7% |
| May 1, 2025 | $0.55 vs $0.48 | +1.4% | −1.5% |
| Feb 20, 2025 | $0.58 vs $0.53 | +3.0% | +9.7% |
| Nov 8, 2024 | $0.80 vs $0.78 | −29.8% | −5.0% |

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. [How stocks move after earnings](https://www.exent.ai/resources/how-stocks-move-after-earnings)

## Where BAX’s revenue comes from

In fiscal 2025 (the year to Dec 31, 2025), BAX’s largest reported region was the United States, with 54.4% of its $11.2 billion revenue. By region: United States 54.4%; Western Europe, Canada, Japan, Australia and New Zealand 33.2%; Emea 12.4%.

By business, the largest segment was Medical Products And Therapies, with 48.8% of $10.9 billion revenue (+1.8% on the year before).

| Segment | Revenue | Share | Growth |
| --- | --- | --- | --- |
| Medical Products And Therapies | $5.3 billion | 48.8% | +1.8% |
| Healthcare Systems and Technologies | $3.1 billion | 28.3% | +4.1% |
| Pharmaceuticals | $2.5 billion | 22.9% | +3.4% |

From BAX’s annual filings; segment growth compares fiscal 2025 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. [Which S&P 500 companies depend most on China?](https://www.exent.ai/resources/sp-500-china-revenue-exposure)

## Members of Congress who traded BAX

As of Oct 20, 2026, **15 members of Congress** had disclosed 100 trades in BAX (56 buys and 44 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated May 1, 2026.

| Trade date | Member | Type | Amount |
| --- | --- | --- | --- |
| May 1, 2026 | [Ro Khanna](https://www.exent.ai/congress/ro-khanna) | Buy | $1,001–$15,000 |
| Mar 23, 2026 | [Michael McCaul](https://www.exent.ai/congress/michael-mccaul) | Buy | $15,001–$50,000 |
| Jan 13, 2026 | [Michael McCaul](https://www.exent.ai/congress/michael-mccaul) | Buy | $50,001–$100,000 |
| Oct 31, 2025 | [Lisa McClain](https://www.exent.ai/congress/lisa-mcclain) | Sale | $1,001–$15,000 |
| Oct 30, 2025 | [Lisa McClain](https://www.exent.ai/congress/lisa-mcclain) | Buy | $1,001–$15,000 |
| Oct 30, 2025 | [Lisa McClain](https://www.exent.ai/congress/lisa-mcclain) | Sale | $1,001–$15,000 |
| Sep 29, 2025 | [Ro Khanna](https://www.exent.ai/congress/ro-khanna) | Buy | $1,001–$15,000 |
| Sep 25, 2025 | [Lisa McClain](https://www.exent.ai/congress/lisa-mcclain) | Buy | $1,001–$15,000 |
| Sep 5, 2025 | [Ro Khanna](https://www.exent.ai/congress/ro-khanna) | Sale | $1,001–$15,000 |
| Sep 3, 2025 | [Ro Khanna](https://www.exent.ai/congress/ro-khanna) | Sale | $1,001–$15,000 |

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. [See every member’s disclosed trades](https://www.exent.ai/congress)

## Are BAX insiders buying or selling?

In the 12 months to Oct 20, 2026, BAX insiders made **no open‑market purchases** and **no sales**, according to SEC Form 4 filings. The last open‑market purchase on record was on Mar 30, 2020.

After the 4 insider purchases of $10,000 or more since 2012, BAX lagged the S&P 500 by an average of 12.2 percentage points over the next 12 months; 25% of them were followed by a beat (a small sample). Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

| Date | Insider | Role | Value |
| --- | --- | --- | --- |
| Mar 30, 2020 | Martin Sean | SVP and General Counsel | $803,818 |
| May 23, 2016 | Almeida Jose E | Director, officer: Chairman of the Board and CEO | $499,790 |
| Apr 24, 2014 | Stroucken Albert P L | Director | $3,619 |
| Mar 25, 2014 | Stroucken Albert P L | Director | $3,740 |
| Mar 20, 2014 | Stroucken Albert P L | Director | $5,459 |

The table lists the latest open‑market purchases on record, leaving out the last 30 days. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. [Do insider buys beat the market?](https://www.exent.ai/resources/do-insider-buys-beat-the-market)

## How much of BAX is sold short?

As of the Sep 30, 2026 settlement date, **4.74%** of BAX’s float was sold short: 24.4 million shares, or 3.0 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 5.14%. The median across the 997 US stocks Exent tracks was 4.77%, so BAX is less heavily shorted than most.

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. [The most shorted stocks](https://www.exent.ai/resources/most-shorted-stocks)

## How many institutions own BAX?

At the end of Q2 2026 (Jun 30, 2026), **722 institutions** reported holding BAX in 13F filings, up 29 from the quarter before and down from 810 a year earlier. Their reported holdings add up to 109.2% of BAX’s shares. In the quarter 365 institutions added to their positions and 197 cut them.

- **722** 13F holders

- **111** new positions

- **81** positions closed

- **109.2%** of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. [Which stocks institutions are buying and selling](https://www.exent.ai/resources/institutional-ownership-13f-changes)

## Is BAX diluting shareholders?

BAX’s diluted share count **fell 0.8%** over the five fiscal years to fiscal 2025 and rose 0.6% in fiscal 2025 alone. Each share now owns a larger slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $117.0 million in fiscal 2025, 1.0% of revenue. BAX did not buy back shares in fiscal 2025.

- **+0.6%** share count, 1 year

- **−0.8%** share count, 5 years

- **1.0%** stock pay as % of revenue

- **0.00%** buyback yield

Weighted‑average diluted shares from BAX’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. [Stock dilution and stock‑based compensation, explained](https://www.exent.ai/resources/stock-dilution-and-stock-based-compensation)

## BAX financial health scores

In Exent’s Oct 20, 2026 snapshot, BAX’s Altman Z‑score was **2.30**, in the grey zone (where 149 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was **4 out of 9**; 88% of scored stocks reach 4 or more.

- **2.30** Altman Z‑score: grey zone

- **4/9** Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. [Which stocks have the highest bankruptcy risk?](https://www.exent.ai/resources/altman-z-score-bankruptcy-risk-stocks)

## What BAX talks about on earnings calls

On its latest earnings call (Jul 30, 2026), BAX’s executives and analysts mentioned AI **1 time**, against 6 on the call before (Apr 30, 2026); the average across 455 S&P 500 calls that quarter was 12.9. After AI, the most mentioned topic was tariffs (22).

| Mentions | Jul ’26 | Apr ’26 | Feb ’26 | Oct ’25 |
| --- | --- | --- | --- | --- |
| AI | 1 | 6 | 0 | 0 |
| AI agents | 0 | 0 | 0 | 0 |
| Data centers | 0 | 0 | 0 | 0 |
| Tariffs | 22 | 6 | 7 | 5 |
| China | 0 | 0 | 1 | 3 |
| Recession | 0 | 0 | 0 | 0 |

Word counts in the full transcript of each call, prepared remarks and Q&A, newest first. “AI” also counts generative AI and large language models; “AI agents” counts agentic AI. [Which companies talk most about AI?](https://www.exent.ai/resources/ai-mentions-on-earnings-calls)

## Which ETFs hold BAX?

As of Oct 20, 2026, **45** of the 304 ETFs Exent tracks held BAX. Its largest weight is in FFLC (Fidelity Covington Trust - Fidelity Fundamental Large Cap Core ETF), at 0.45% of the fund.

| ETF | Fund | Weight of BAX |
| --- | --- | --- |
| FFLC | Fidelity Covington Trust - Fidelity Fundamental Large Cap Core ETF | 0.45% |
| [SCHM](https://www.exent.ai/etfs/schm) | Schwab U.S. Mid-Cap ETF | 0.27% |
| [VBR](https://www.exent.ai/etfs/vbr) | Vanguard Small-Cap Value Index Fund ETF Shares | 0.26% |
| [RSP](https://www.exent.ai/etfs/rsp) | Invesco S&P 500 Equal Weight ETF | 0.21% |
| [XLV](https://www.exent.ai/etfs/xlv) | State Street Health Care Select Sector SPDR ETF | 0.20% |
| [VHT](https://www.exent.ai/etfs/vht) | Vanguard Health Care Index Fund ETF Shares | 0.17% |
| [VB](https://www.exent.ai/etfs/vb) | Vanguard Small-Cap Index Fund ETF Shares | 0.16% |
| [DFAS](https://www.exent.ai/etfs/dfas) | Dimensional U.S. Small Cap ETF | 0.15% |

Owning several of these funds stacks the same position. [How much do VOO, QQQ and VTI overlap?](https://www.exent.ai/resources/etf-overlap-voo-qqq-vti)

## The right benchmark for BAX

Exent matches every holding to the index with the most similar risk. For BAX that is **MDY**. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read [why the S&P 500 is the wrong benchmark for most portfolios](https://www.exent.ai/resources/why-the-sp-500-is-the-wrong-benchmark).

## Other healthcare stocks

| Ticker | Name | 5‑year return | Volatility (5y) |
| --- | --- | --- | --- |
| [LLY](https://www.exent.ai/stocks/lly) | Eli Lilly and Company | +482.3% | 32.6% |
| [JNJ](https://www.exent.ai/stocks/jnj) | Johnson & Johnson | +92.9% | 16.8% |
| [ABBV](https://www.exent.ai/stocks/abbv) | AbbVie Inc. | +207.1% | 23.5% |
| [PEN](https://www.exent.ai/stocks/pen) | Penumbra, Inc. | +15.3% | 40.7% |
| [SOLV](https://www.exent.ai/stocks/solv) | Solventum Corporation | — | — |
| [AMRX](https://www.exent.ai/stocks/amrx) | Amneal Pharmaceuticals, Inc. | +291.8% | 49.8% |
| [HALO](https://www.exent.ai/stocks/halo) | Halozyme Therapeutics, Inc. | +243.9% | 40.5% |
| [CHE](https://www.exent.ai/stocks/che) | Chemed Corporation | +12.9% | 25.4% |

## Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: [Exent methodology](https://www.exent.ai/methodology).

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

## Check BAX with Exent Gems

Wall Street’s average BAX price target is 8.9% below the latest share price. See what the best‑ranked analysts on BAX say now in Exent Gems.

1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
2. Gems shows who the top‑ranked analysts covering BAX are, their live calls and the median target of only the top‑rated analysts.
3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product: [Exent Gems](https://www.exent.ai/radar)

Also: [Stress‑test your portfolio with BAX](https://www.exent.ai/portfolio)

## Frequently asked questions

### Did BAX beat the S&P 500 over the last 10 years?

No. BAX returned −43.5% (−5.5% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

### Is BAX in the S&P 500?

Yes. As of Oct 20, 2026, BAX (Baxter International Inc.) is one of the 503 stocks in the S&P 500.

### How much did BAX fall in the 2008 crash?

BAX fell −31.8% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.

### How much did BAX fall in the COVID crash?

BAX fell −23.2% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

### How much did BAX fall in the 2022 bear market?

BAX fell −39.8% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

### What is BAX’s Sharpe ratio?

Over the 5 years to Oct 30, 2026, BAX’s Sharpe ratio was −0.59 and its Sortino ratio −0.74, versus 0.58 and 0.91 for the S&P 500.

### Is BAX a volatile stock?

BAX’s 5‑year annualized volatility was 36.1%, higher than the S&P 500’s 17.0%, with a beta of 0.68.

### What is least correlated with BAX?

Among large US stocks, the lowest correlations with BAX over the last 60 months were PLTR (−0.18), VRT (−0.16), CDNS (−0.16). Its correlation with long Treasuries (TLT) was 0.27 and with gold (GLD) 0.15.

### Does BAX usually beat earnings estimates?

BAX beat the consensus earnings-per-share estimate in 10 of its last 12 quarterly reports through Jul 30, 2026, and the revenue estimate in 10 of 12. The stock moved 7.7% on average, up or down, from the close before each report to the close after it.

### Have members of Congress traded BAX?

Yes. As of Oct 20, 2026, 15 members of Congress had disclosed 100 trades in BAX (56 buys and 44 sales) in STOCK Act disclosures filed with the House and Senate.

### What is BAX’s short interest?

As of the Sep 30, 2026 settlement date, 4.74% of BAX’s float was sold short (24.4 million shares, 3.0 days to cover), according to FINRA short-interest reports. A year earlier it was 5.14%.

### Is BAX diluting shareholders?

No. BAX’s diluted share count fell 0.8% over the five fiscal years to fiscal 2025 and rose 0.6% in the latest year. Stock-based compensation was 1.0% of revenue.

---

Educational content, not investment advice. Past performance does not guarantee future results.
